



ISSN Print: 2394-7500
ISSN Online: 2394-5869
Impact Factor: 5.2
IJAR 2016; 2(12): 818-821
www.allresearchjournal.com
Received: 19-10-2016
Accepted: 22-11-2016

Soumyadarshan Nayak
Department of Neurology, SCB
Medical College, Odisha, India

Saumya Nanda
Department of Obstetrics and
Gynaecology, SCB Medical
College, Odisha, India

Prevalence of colistin resistance in isolated *Acinetobacter baumannii* at a Neuro-ICU setup in a tertiary care hospital in Odisha

Soumyadarshan Nayak and Saumya Nanda

Abstract

Background: The gram-negative bacteria *Acinetobacter baumannii* is often a causative organism of nosocomial infections like meningitis, bacteremia, pneumonia, and urinary tract infections. *A. Baumannii* is an emerging agent of nosocomial infections worldwide. Colistin is the ultimate anti-microbial agent for the treatment of multidrug-resistant *A. Baumannii*, and in recent times, colistin-resistance is being suggested from all around the world.

Materials and Method: This prospective observational study was carried out between January 2014-Jan 2016 (Study period: 2 years) on one hundred *A. Baumannii* samples removed from bed-sore swabs, urine, respiratory secretions, and blood of patients admitted to the intensive care unit of IMS and SUM Hospital, Bhubaneswar, Odisha, India. The micro-organisms were identified through microscopy and biochemical tests. The disk diffusion method with colistin disk (Himedia, Mumbai, India) was utilized to discover the resistance to colistin.

Results: A total of hundred *A. Baumannii* micro-organisms have been identified, of which 93 had been sensitive and seven with proof of colistin-resistance, consistent with the disk diffusion test.

Conclusion: The outcomes confirmed the presence of resistance of *A. Baumannii* to colistin, in Neuro-ICU set-up in a Tertiary care centre in Bhubaneshwar, Odisha.

Keywords: *Acinetobacter baumannii*, disk diffusion, multidrug resistance, Colistin

Introduction

Acinetobacter baumannii is a Gram negative, non-fermenting, opportunistic isolate that is recognized as a major nosocomial pathogen. It can cause infections at various anatomical sites; bacteremia, pneumonia, meningitis and urinary tract infection, most commonly in immunocompromised and critical care patients in the Neuro-ICU. The capacity to endure on dry surfaces and its relative resistance to disinfectants allows this non-fermenter to survive well in the hospital environment^[1]. *A. baumannii* isolates are resistant to almost all available antibiotics including β -lactams, *Fluoroquinolone*, *Tetracycline*, aminoglycosides and carbapenems^[2]. More importantly, pandrug-resistant and extremely drug-resistant isolates have emerged^[3] and are on the rise worldwide. Colistin (polymyxin E) and tigecycline are frequently the only antibiotics remaining to treat multidrug resistant (MDR) *A. baumannii* infections^[4]. However, hetero-resistance and resistance against colistin have been reported in clinical settings throughout the world^[5]. Here we review the reports all over the world and epidemiology of colistin resistance in *A. baumannii*.

Resistance against Colistin

Colistin, a natural substance produced by *Bacillus polymyxa* and a cationic lipopeptide (cyclic decapeptide) discovered in 1949. It has not typically been included in regimens to treat *Acinetobacter* infections because (Albeit debatable) of its neurotoxicity and nephrotoxicity. However, it has been as a therapeutic option for the treatment of ventilator associated pneumonia caused by drug resistant gram-negative organisms^[6]. Colistimethate sodium and Colistinsulfate are two commercially available forms and recently colistin has progressively been used as rescue therapy for severe infections in critically ill patients^[7]. It is bactericidal against Gram negative bacteria; its amphiphilic nature allows it to interact with lipid A moiety of lipopolysaccharide (LPS) causing disarray in the bacterial outer membrane.

Corresponding Author:
Saumya Nanda
Department of Obstetrics and
Gynaecology, SCB Medical
College, Odisha, India

Colistin consists of cyclic heptapeptide covalently attached to a fatty acyl chain^[8]. Typically colistin resistance is by chromosomally mediated modulations. There is relatively little research has been done on colistin resistance in *A. baumannii* and there are two main hypotheses of colistin resistance. The first hypothesis of colistin resistance is mediated by loss of LPS production, caused by mutations in any of lipid A biosynthesis genes (*lpxA*, *lpxC* and *lpxD*) terminating complete production of LPS. Furthermore, presence of insertion sequence ISA ba11 in either *lpxC* or *lpxA* not only causes loss of LPS production but also causes high level colistin resistance^[9]. In countering to total LPS loss, *A. baumannii* modify the expression of critical transport and biosynthesis systems associated with modulating the composition and structure of the bacterial surface. Eventually, LPS deficiency causes less negative charge and thus might be the reason for the loss of affinity towards colistin^[10]. Secondly, colistin resistance has been hypothesized to PmrAB-two component response regulator and sensor kinase system. This system allows bacteria to sense and respond to various environmental conditions such as pH or Fe³⁺ and Mg²⁺ levels, also affecting expression of genes implicated in lipid A modification and thus causing colistin resistance^[11]. Point mutations in *pmrA* and *pmrB* genes of PmrAB two-component regulatory system showed upregulated expression of *pmrAB*. The increase expression results in remodeling of bacterial membrane causing decreased membrane permeability^[12]. Recently, colistin resistance has shown to be singularly due to plasmid mediated *mcr-1* gene. Although there is no report of *mcr-1* being detected in *A. baumannii*, the prevalence has been investigated in *E. coli* and *K. pneumoniae*.^[13,14] If *mcr-1* gene is similar to NDM-1 colistin resistance could become endemic in the world. The rapid dissemination of previous antibiotic resistance indicates that, with the advent of transmissible colistin resistance, progression of *A. baumannii* from multidrug to pandrug resistance is unavoidable. Although the levels of maximum inhibitory concentration of colistin are not high (4–8 mg/L), acquaintance of *mcr-1* by carbapenem resistance *A. baumannii* isolates will make them resistance to all antibiotics^[14]. The potential of *mcr-1* to become global depend upon several factors: use of irrational doses of colistin, the stability of *mcr-1* mediated plasmid and their ability to transfer in humans. Effective strategies that limit selection and further dissemination of plasmid associated *mcr-1* are clearly needed. It is important to prevent the dissemination of colistin by developing agents which provide effective reverse resistance strategies. Lately, colistin resistance has been found due to efflux pumps [15] in which efflux pump inhibitors (EPIs) were used to suppressed colistin resistance. Colistin resistance has been attributed to efflux pumps belonging to RND (resistance-nodulation-cell division) family^[16]. The efflux pump consists of two component regulatory system mediating adaptive response of bacterial cells to a range of environmental stimuli. Genes are organized as operon *adeA*, *adeB*, and *adeC* and regulated by *adeR* gene. *adeA* is a membrane fusion protein and *adeC* is an outer membrane protein channel, in which *adeB* acquire its substrate and transports from cytoplasm or within phospholipid bilayer to extracellular medium^[17]. In this study we have found the incidence of colistin resistance on *A. baumannii* from a tertiary care teaching hospital in Bhubaneswar, Odisha.

Material and Methods

This study was carried out during 24 months in the Neurointensive care unit of IMS and SUM Hospital, Bhubaneswar Hospital in Odisha. Sampling was performed from bed sore swabs, ulcers, blood, and respiratory secretions of patients admitted to ICU. The bacteria were cultured in Eosin Methylene Blue, blood agar, and MacConkey's agar media. After inoculation, the samples were placed on the relevant culture medium. The cultured plates were then incubated at 37 °C for 18-24 hours. *A. baumannii* (Fig 1) was recognized using the tests catalase, oxidase, TSI, and motility; other biochemical tests were performed and antibiogram (Fig 2) was performed on 100 purified samples through the following general procedure. To prepare a suspension of *A. baumannii* with turbidity equal to that of half McFarland, a number of *A. baumannii* colonies were dissolved in some sterile normal saline to produce a suspension with half McFarland turbidity; a swab was entered in the suspension and its extra solution was squeezed, the swab was then streaked slowly in different directions on Mueller Hinton agar medium so that its entire surface was covered uniformly with the bacteria; after the surface was dried (not to be more than a quarter), antibiotics disks (Himedia, Mumbai) were placed on the medium at least 2 cm apart from each other using sterile forceps; the plates were then incubated at 35 °C for 18-24 hours. Finally, the zone of inhibition was measured with a ruler and matched with CLSI tables for different antibiotics.

Results

All 100 isolates identified as *A. baumannii* in this study had the same biochemical pattern. *A. baumannii* produced pale pink mucoid colonies on blood agar (without hemolysis and pigment) and MacConkey's agar media. At the end of this study, 100 strains of *A. baumannii* were recovered in IMS and SUM Hospital, Bhubaneswar Hospital using microscopy and biochemical tests and by eliminating unrelated and repeated isolates. Most isolates were isolated from bed sore swabs (Table 1). A total of 93 *A. baumannii* isolates sensitive to colistin and 7 resistant isolates were documented in IMS and SUM Hospital, Bhubaneswar.

Table 1: Percentage of distribution of *A. baumannii* isolates based on clinical samples

Sample	Number
Blood	18
Tracheal aspiration	11
Ulcer	26
Bed sore swab	45
Total	100



Fig 1: Pure culture of *A. baumannii* on nutrient agar




Fig 2: Colistin resistance and sensitive

Discussion

High resistance of *Acinetobacter baumannii* to different antibiotics and prevalence of multidrug-resistant strains (MDR), especially in immunosuppressed patients, makes difficult the control and treatment of the disease. Infections caused by this microorganism have a negative impact on clinical outcomes and treatment costs. As a nosocomial-inducing bacterium, *A. baumannii* creates many health problems in hospitals in Iran like the rest of the world; therefore, knowledge of its resistance to colistin is of great importance in the treatment of *A. baumannii*-induced infections. In comparison with similar studies in other regions of Iran, the frequency of colistin-resistant isolates of *A. baumannii* was high in this study. The difference in these findings may represent the increasing resistance of these strains to colistin, so that comparison of the studies confirms this increment over time. In this research, 7% of the isolates were resistant to colistin which was the greatest resistance rate compared with other studies. Reports are increasing after the first report of colistin-resistant *Acinetobacter* spp. in 1999 in the Czech Republic [7]. Li *et al.* described colistin-resistant *A. baumannii* for the first time in 2006 [8]. The resistant of *A. baumannii* to colistin in clinical isolates is a serious danger, suggesting that if colistin is inappropriately used, a rapid increase in resistance and treatment failure are likely to occur. The antimicrobial surveillance department including the United States of America, Europe, Latin America, and Asia-Pacific region indicated that the resistance of *A. baumannii* to colistin remained at a low level from 2001 to 2011 (0.9%-3.3%) [9-11]. Other reports of colistin-resistant *A. baumannii* were obtained from Asia, Europe, North America, and South America. Ten reports from Europe, including 2 case reports, provided information about colistin-resistant *A. baumannii* [12-13]. The rate was less than 7% in most of these reports; [14], however the rates of two reports from Bulgaria and Spain were 16.7% and 19.1%, respectively [15-16]. Interestingly, this rate was 40.7% in another report from Spain in which the cases were recruited from a three-care hospital between 2000 and November 2006. According to [15], the rate in 7 out of 8 reports from Asia was less than 12%. Koet *al.* reported the highest rate of colistin resistance as 30.6% in Korea [17-20]. Out of 3 reports from the United State [21], 2 had a relatively low resistance not more than 1.2% [22, 23]. The rate of resistance was not more than 1.7% in South America [24]. Asia and Europe have the most serious situation in terms of resistance to colistin, and have more reports and higher resistance rates, while North and South America had a lower rate of colistin-resistant *A. baumannii* and fewer reports in this regard. Comparison of the results of this research with

similar studies indicates increasing prevalence of nosocomial infections caused by colistin-resistant *A. baumannii*. According to the result obtained in this study and other regions of the world, the isolates of *A. baumannii* resistant to colistin are increasing in Iran, and infections caused by these microorganisms will adversely affect clinical outcomes and treatment costs. Spread of colistin-resistant *A. baumannii* in Iran is similar to Korea in Asia and shows that this colistin-resistant organism is increasing in Asia. Since no new drug is on the way to replace the existing drugs against Gram-negative pathogens, and no wide coverage vaccine exists against these infections, the only way to mitigate the spread of infection is to control the bacteria prevalence. This is only achievable by completely understanding the causes, dynamics, and complexity of the occurrence of these organisms.

Conclusion

This research isolated colistin-resistant *A. baumannii* strains from SUM hospital in Bhubaneswar; this necessitates adopting appropriate treatment regimen and application of detailed strategies for prevention of nosocomial infections caused by these bacteria.

References

- Henry R, Vithanage N, Harrison P, Seemann T, Coutts S. Colistin-resistant, lipopolysaccharide-deficient *Acinetobacter baumannii* responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-beta-1,6-N-acetylglucosamine. *Antimicrob Agents Chemother.* 2012; 56:59-69.
- Gordon NC, Wareham DW. Multidrug-resistant *Acinetobacter baumannii*: Mechanisms of virulence and resistance. *Int J Antimicrob Agents.* 2010; 35:219-226.
- Park YK, Peck KR, Cheong HS, Chung DR, Song JH. Extreme drug resistance in *Acinetobacter baumannii* infections in intensive care units, South Korea. *Emerg Infect Dis.* 2009; 15:1325-1327.
- Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of *Acinetobacter baumannii*: clinical reports, mechanisms and antimicrobial strategies. *J Antimicrob Chemother.* 2012; 67:1607-1615.
- Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K. Rapid dissemination of colistin and carbapenem resistant *Acinetobacter baumannii* in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. *BMC Infect Dis.* 2015; 15:559.

6. Guidelines for the management of adults with hospital-acquired ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med.* 2005; 171:388-416.
7. Oleksiuk LM, Nguyen MH, Press EG, Updike CL, O'Hara JA. *In vitro* responses of *Acinetobacter baumannii* to two- and three-drug combinations following exposure to colistin and doripenem. *Antimicrob Agents Chemother.* 2014; 58:1195-1199.
8. Pristovsek P, Kidric J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study. *J Med Chem.* 1999; 42:4604-4613.
9. Moffatt JH, Harper M, Adler B, Nation RL, Li J. Insertion sequence ISAb11 is involved in colistin resistance and loss of lipopolysaccharide in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2011; 55:3022-3024.
10. Soon RL, Nation RL, Cockram S, Moffatt JH. Different surface charge of colistin-susceptible and -resistant *Acinetobacter baumannii* cells measured with zeta potential as a function of growth phase and colistin treatment. *J Antimicrob Chemother.* 2011; 66:126-133.
11. Beceiro A, Llobet E, Aranda J, Bengochea JA, Doumith M. Phosphoethanolamine modification of lipid A in colistin-resistant variants of *Acinetobacter baumannii* mediated by the pmr AB two component regulatory system. *Antimicrob Agents Chemother.* 2011; 55:3370-3379.
12. Kim SH, Jia W, Parreira VR, Bishop RE, Gyles CL. Phosphoethanolamine substitution in the lipid A of *Escherichia coli* O157 : H7 and its association with PmrC. *Microbiology.* 2006; 152:657-666.
13. Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B. Detection of mcr-1 encoding plasmid-mediated colistin-resistant *Escherichia coli* isolates from human bloodstream infection and imported chicken meat, Denmark. *Euro Surveill.* 2015, 20.
14. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis.* 2016; 16:161-168.
15. Ni W, Li Y, Guan J, Zhao J, Cui J. Effects of Efflux Pump Inhibitors on Colistin Resistance in Multidrug-Resistant Gram-Negative Bacteria. *Antimicrob Agents Chemother.* 2015; 60:3215-3218.
16. Modarresi F, Azizi O, Shakibaie MR, Motamedifar M, Valibeigi B. Effect of iron on expression of efflux pump (adeABC) and quorum sensing (luxI, luxR) genes in clinical isolates of *Acinetobacter baumannii*. *APMIS.* 2015; 123:959-968.
17. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in *Acinetobacter baumannii* strain BM4454. *Antimicrob Agents Chemother.* 2001; 45:3375-3380.
18. Hejnar P, Kolar M, Hajek V. Characteristics of *Acinetobacter* strains (phenotype classification, antibiotic susceptibility and production of β -lactamases), 1999.
19. Li J, Rayner CR, Nation RL. Heteroresistance to colistin in multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2006; 50:2946-50.
20. Gales AC, Reis AO, Jones RN. Contemporary Assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review available interpretative criteria and quality control guidelines. *J Clin. Microbiol.* 2001; 39:183-190.
21. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). *J Antimicrob Chemother.* 2011; 66:2070-4.
22. Yau W, Owen RJ, Poudyal A. Colistin hetero-resistance in multidrug-resistant *Acinetobacter baumannii* clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. *J Infect.* 2009; 58:138-44.
23. Rolain JM, Roch A, Castanier M. *Acinetobacter baumannii* Resistant to colistin with impaired virulence: a case report from France. *J Infect Dis.* 2011; 204:1146-7.
24. Lopez-Rojas R, Jimenez-Mejias ME, Lepe JA. *Acinetobacter baumannii* resistant to colistin alters its antibiotic resistance profile: a case report from Spain. *J Infect Dis.* 2011; 204:1147-8.
25. Hejnar P, Kolar M, Hajek V. Characteristics of *Acinetobacter* strains (phenotype classification, antibiotic susceptibility and production of β -lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. *Acta Univ Palacki Olomuc Fac Med.* 1999; 142:73-7.
26. Arroyo LA, Mateos I, Gonzalez V. *In vitro* activities of tigecycline, minocycline, and colistin/tigecycline combination against multi- and pandrug-resistant clinical isolates of *Acinetobacter baumannii* group. *Antimicrob Agents Chemother.* 2009; 53:1295-6.
27. Dobrewski R, Savov E, Bernards AT, van den M, Barselaar P, Nordmann PJ, van den Broek, and L. Dijkshoorn. Genotypic diversity and antibiotic susceptibility of *Acinetobacter baumannii* isolates in a Bulgarian hospital. *Clin. Microbiol. Infect.* 2006; 12:1135-1137.
28. Garcia-Penuela E, Aznar E, Alarcon T, Lopez-Brea M. Susceptibility pattern of *Acinetobacter baumannii* clinical isolates in Madrid vs. Hong Kong. *Rev. Esp. Quimioter.* 2006; 19:45-50.
29. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in *Acinetobacter* species isolated from patients in Kuwait hospitals. *J Chemother.* 2011; 23:13-6.
30. Ko KS, Suh JY, Kwon KT. High rates of resistance to colistin and polymyxin B in subgroups of *Acinetobacter baumannii* isolates from Korea. *J Antimicrob Chemother.* 2006; 60:1163-7.
31. Lee SC, Huang SS, See LC. *In vitro* activities of nine current antibiotics against culprit bacteria in nosocomial infections in an institution in northern Taiwan. *Chang Gung Med J.* 2011; 34:580-9.
32. Doi Y, Husain S, Potoski BA. Extensively drug-resistant *Acinetobacter baumannii*. *Emerg Infect Dis.* 2009; 15:980-2.
33. Hawley JS, Murray CK, Griffith ME. Susceptibility of *Acinetobacter* strains isolated from deployed U.S. military personnel. *Antimicrob Agents Chemother.* 2007; 51:376-8.
34. Keen EF III, Robinson BJ, Hospenthal DR. Prevalence of multidrug-resistant organisms recovered at a military burn center. *Burns.* 2010; 36:819-25.
35. Tognim MC, Gales AC, Penteado AP. Dissemination of IMP-1 metallo- β -lactamase-producing *Acinetobacter* species in a Brazilian teaching hospital. *Infect Control Hosp Epidemiol.* 2006; 27:742-7.